$1.34
+0.02 (+1.52%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MNOV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 9 with posted results
Held by 5 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Schonfeld Strategic Advisors LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 8.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: MN-166, placebo | Amyotrophic Lateral Sclerosis | 234 | Apr 2027 | ≤ 254 d | 2026-03-06 |
| MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24Randomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: MN-001, MN-001 placebo | Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease | 40 | 2026-12-31 | in 134 d | 2026-02-05 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaNCT03782415Evaluate safety and tolerability of ibudilast and temozolomide combination treatmentOpen-label · Treatment | Phase 1/2 | Completed | Drug: MN-166, Temozolomide | Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma | 64 | 2023-08-07actual | — | 2025-05-21 |
| Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSNCT04429555results2024-10-30Number of Participants Free From Respiratory Failure at Day 7Randomized · Double-masked · TreatmentStudy Protocol, Statistical Analysis Plan, and Informed Consent Form ↗ | Phase 2 | Completed | Drug: Ibudilast, Placebo | Pneumonia, Viral | 34 | 2022-06-30actual | — | 2024-10-30 |
| Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisNCT02503657results2026-01-23Absolute Change From Baseline in Forced Vital Capacity for 26 WeeksRandomized · Quadruple-masked · TreatmentStudy Protocol and Informed Consent Form ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MN-001, Placebo | Idiopathic Pulmonary Fibrosis, IPF | 15 | 2020-12-07actual | — | 2026-01-23 |
| A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)NCT02714036results2024-09-24Impact of MN-166 on [11C]-PBR28 Uptake in the Motor Cortices and Brain Stem Measured by Positron Emission Tomography (PET) Imaging at 12 - 24 WeeksNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: ibudilast, Ibudilast | Amyotrophic Lateral Sclerosis | 35 | 2019-12-31actual | — | 2024-09-24 |
| Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersNCT04054206Compare the pharmacokinetic profile of ER and IR formulations in single-dose administration of MN-166 (ibudilast)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MN-166 | Healthy Volunteers | 12 | 2019-07-17actual | — | 2020-07-15 |
| Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy VolunteersNCT03533387Compare the PK Profile of two new formulations in Single-day dose of MN-166Randomized · Open-label · Other | Phase 1 | Completed | Drug: MN-166 | Healthy Volunteers | 28 | 2018-07-06actual | — | 2019-05-31 |
| Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsNCT02681055results2023-03-15Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux CapacityOpen-label · TreatmentStudy Protocol, Statistical Analysis Plan, and Informed Consent Form ↗ | Phase 2 | Completed | Drug: MN-001 | Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia | 19 | 2018-05-30actual | — | 2023-03-15 |
| Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)NCT02238626results2021-11-05Safety and Tolerability of MN-166 60 mg/d Versus Placebo When Administered With Riluzole in Subjects With ALSRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo (for MN-166), MN-166, riluzole | Amyotrophic Lateral Sclerosis | 70 | Aug 2017actual | — | 2021-11-05 |
| Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisNCT01982942results2020-07-28Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).Randomized · Triple-masked · TreatmentStudy Protocol, Statistical Analysis Plan, and Informed Consent Form ↗ | Phase 2 | Completed | Drug: ibudilast, Placebo oral capsule | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 255 | May 2017actual | — | 2020-07-28 |
| Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT01551316Number of Participants with Adverse Events as a Measure of Safety and TolerabilityRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: MN-221, Placebo | Chronic Obstructive Pulmonary Disease | 19 | May 2012actual | — | 2012-05-21 |
| Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of AsthmaNCT00838591The primary efficacy analysis will be based on a change in FEV1, expressed as percent of predicted, at Hour 3 when compared to FEV1, expressed as percent of predicted, at the qualifying/screening timepoint.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: MN-221, Placebo | Asthma | 176 | Mar 2012actual | — | 2013-09-05 |
| Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01013142Adverse events, cardiac and ECG parameters, vital signs, physical exam and clinical laboratory assessments.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3) | Chronic Obstructive Pulmonary Disease | 48 | Mar 2010actual | — | 2015-05-13 |
| Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of AsthmaNCT00683449results2011-07-29Change of FEV1 (Forced Expiratory Volume in 1 Second) Expressed as Percent of Predicted After Two Doses of Albuterol (5 mg Each) and Ipratropium (0.5 mg Each) When Compared to FEV1 at Hour 2 After the Start of the Infusion of MN-221 or Placebo.Randomized · Single-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more appropriate dosing scheme for MN-221 in subjects with asthma. | Drug: Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3 | Asthma, Status Asthmaticus | 29 | Mar 2009actual | — | 2011-10-07 |
| Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe AsthmaNCT00679263results2011-12-15Number of Patients Reported to Have Adverse EventsRandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: MN-221, MN-221, Placebo | Asthma | 17 | Jul 2008actual | — | 2011-12-19 |
| Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisNCT00295854results2012-01-19Number Subjects at Least "Moderately Improved" for Each Treatment Group in Patient Reported Global Response Assessment (GRA)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: MN-001 BID, MN-001, Placebo | Interstitial Cystitis | 296 | Oct 2006actual | — | 2012-01-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19